Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Regeneron

US stocks today: Nasdaq falls as technology stocks slide, Treasury yields climb

US stocks closed mixed as Nasdaq slipped due to profit booking and rising Treasury yields, while Dow edged higher. Oil prices surged on supply disruption fears but later eased after geopolitical comments. Energy stocks outperformed, Nvidia earnings are awaited, and Regeneron fell after a failed drug trial result.

The Economic Times

Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.

Regeneron stock sinks as fianlimab Phase 3 trial fails to meet primary endpoint. But RBC continues to see significant upside in REGN shares from here.

Barchart

Appian Pitches Reliable AI, $825M Revenue Goal and Bigger Buyback at Investor Day

Appian (NASDAQ:APPN) executives used the company’s Investor Day 2026 in New York to frame the software maker as a provider of “complex process automation” for regulated industries and as a platform for making artificial intelligence more reliable in enterprise workflows. Chief Financial Officer Ser

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

CRISPR Genome Editing and the Future of Down Syndrome Treatment

The ethics of using safe gene therapies to improve the health and cognition of Down syndrome children and adults.

Reason

Trump Appears to Doze Off During Live Oval Office Event as Video of Him Mocking 'Sleepy Joe' Biden Resurfaces

President Trump, 79, appeared to nod off during a live Oval Office event, sparking renewed scrutiny over his health. The incident contrasts with his past criticism of Biden's on-camera drowsiness.

International Business Times UK

'A landmark moment for the field': FDA approves first-ever gene therapy for inherited deafness

A gene therapy made by Regeneron is the first treatment of its kind approved for genetic hearing loss.

LiveScience

Trump will unveil a deal with Regeneron to lower drug prices

President Donald Trump is set to announce a deal with Regeneron to lower drug costs as part of the White House's effort to lower drug prices

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Trump cuts drug price deal with Regeneron

Regeneron is the last of 17 companies the administration pressed to commit to the "most favored nation" policy.

Axios

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Tuesday reported third-quarter adjusted earnings of $11.83 per share, down 5% year-over-year, beating the consensus of $9.59.

Benzinga

Regeneron's Gene Therapy Shows Significant Gains In Genetic Hearing Loss

On Sunday, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) unveiled updated data from its investigational gene therapy DB-OTO for profound genetic hearing loss caused by variants of the otoferlin (OTOF) gene.

Benzinga

Regeneron's Libtayo Gains FDA Approval To Reduce Recurrence Risk In Skin Cancer Patients

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) PD-1 inhibitor Libtayo (cemiplimab-rwlc) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation.

Benzinga

The Best Biotech ETFs to Buy

Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector.

Kiplinger

FDA Expands Use Of Regeneron's Evkeeza To Infants With Rare Cholesterol Disorder

The U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals, Inc.’s (NASDAQ: REGN) Evkeeza (evinacumab-dgnb) ANGPTL3 antibody as an adjunct to diet and exercise and other lipid-lowering therapies for the treatment of children from age 1 to less than 5 years old with homozygous familial hypercholesterolemia (HoFH).

Benzinga

Regeneron Touts Positive Data From Phase 3 Study In Patients With Ultra-Rare Genetic Disorder

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported positive results from its Phase 3 OPTIMA trial of garetosmab in adults with fibrodysplasia ossificans progressiva (FOP), meeting the study's primary endpoint.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

What's Happening With Regeneron Pharmaceuticals Stock On Monday?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) revealed data from Phase 3 trials in adults with moderate-to-severe cat or birch allergies on Monday. Both trials met their respective primary and key secondary endpoints.

Barchart

How Is Regeneron’s Stock Performance Compared to Other Pharma Stocks?

Regeneron Pharmaceuticals has significantly underperformed the broader pharma space over the past year, yet analysts remain optimistic about the stock’s prospects.

Benzinga

Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday shared data from the Phase 3 NIMBLE trial assessing investigational cemdisiran monotherapy in adults with generalized myasthenia gravis (gMG).

Barchart

Worried About a Market Crash? Here Are 3 Stocks That ‘Big Short’ Star Michael Burry Loves Here.

Here are three top stocks that the ‘Big Short’ star Michael Burry owns in Q2 of 2025. Are UNH, REGN, and LULU undervalued right now?

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported upbeat second-quarter earnings.

Benzinga

Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% year-over-year, beating the consensus of $8.57.

Benzinga

Regeneron Pharmaceuticals Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will release earnings results for the second quarter, before the opening bell on Friday, Aug. 1.

Fortune

Dozens of states sue to block the sale of 23andMe’s genetic data after its former CEO pushes the purchase price $50 million higher

The possible sale of 23andMe’s genetic data could set a precedent for future cases where companies look to offload increasingly personal data.

International Business Times

States Challenge 23andMe Over Genetic Data Sale in Bankruptcy Deal

States sue to halt Regeneron's 23andMe acquisition, citing privacy concerns over user DNA data, as a court-ordered report on the deal's impact looms.

The Guardian - US

23andMe back on the auction block after former CEO makes 11th-hour bid

Anne Wojcicki, ex-CEO of the DNA testing firm, put in a $305m bid, upending Regeneron’s $256m agreement

Barchart

Regeneron Pharmaceuticals Stock: Is Wall Street Bullish or Bearish?

Despite Regeneron Pharmaceuticals' underperformance relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.